- Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis - - Combining three orally administered once-daily LDL-C lowering medicines has ...

Forbes contributors publish independent expert analyses and insights. I'm a medical journalist covering cardiology news. Merck said yesterday that the FDA had accepted Merck's resubmission of its NDA, ...

For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved ...

Dallas, TX - The US Food and Drug Administration (FDA) has approved a new lipid-lowering combination tablet that includes atorvastatin, which went off patent in 2011, and ezetimibe (Zetia, ...

STOCKHOLM—New results suggest that combination therapy with ezetimibe/simvastatin, when prescribed at the recommended starting and next higher doses, is more likely to improve lipids than atorvastatin ...

Orlando, FL - Data presented this week showed torcetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, used alone and in combination with atorvastatin (Lipitor®, Pfizer), increased ...

Tokyo, Japan, August 26, 2009 - Pfizer Japan Inc. ("Pfizer") and Astellas Pharma Inc. ("Astellas") today announced that the companies have reached a co-promotion agreement for a combination drug of ...

The MarketWatch News Department was not involved in the creation of this content. -- Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in ...

- Combining three orally administered once-daily LDL-C lowering medicines has not been previously studied, though combination therapy is common in other areas of cardiovascular medicine1 - - Results ...